Pharvaris N.V. (NASDAQ:PHVS) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

by · The Cerbat Gem

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $59.87.

PHVS has been the subject of a number of recent research reports. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Friday, July 17th. Morgan Stanley boosted their price target on Pharvaris from $46.00 to $62.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 9th. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price objective on shares of Pharvaris in a research note on Monday, September 14th. Finally, Citizens Jmp raised their price objective on Pharvaris from $75.00 to $79.00 and gave the company a “market outperform” rating in a research report on Wednesday, September 9th.

Check Out Our Latest Report on Pharvaris

Insider Buying and Selling at Pharvaris

In related news, Director Elisabeth Bjork sold 52,500 shares of the stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $37.89, for a total transaction of $1,989,225.00. Following the completion of the sale, the director owned 15,167 shares of the company’s stock, valued at $574,677.63. This represents a 77.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO David W. Nassif sold 6,000 shares of the stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $36.47, for a total transaction of $218,820.00. Following the sale, the chief financial officer directly owned 114,300 shares of the company’s stock, valued at $4,168,521. The trade was a 4.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 513,102 shares of company stock valued at $18,643,666.

Hedge Funds Weigh In On Pharvaris

A number of large investors have recently made changes to their positions in the business. venBio Partners LLC acquired a new stake in shares of Pharvaris in the 2nd quarter worth $160,569,809. Wellington Management Group LLP raised its stake in Pharvaris by 12.9% in the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after buying an additional 274,034 shares during the last quarter. Commodore Capital LP boosted its holdings in Pharvaris by 1.6% in the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock worth $54,211,000 after acquiring an additional 29,525 shares in the last quarter. 5AM Venture Management LLC acquired a new stake in Pharvaris in the second quarter worth about $27,581,008. Finally, Seven Fleet Capital Management LP grew its stake in shares of Pharvaris by 144.6% during the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after acquiring an additional 457,804 shares during the last quarter.

Pharvaris Stock Performance

NASDAQ PHVS opened at $30.49 on Tuesday. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of -10.00 and a beta of -2.46. The company’s 50-day simple moving average is $34.98 and its two-hundred day simple moving average is $32.22. Pharvaris has a one year low of $20.65 and a one year high of $43.25.

Pharvaris (NASDAQ:PHVS – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Equities analysts expect that Pharvaris will post -3.12 earnings per share for the current fiscal year.

Pharvaris Company Profile

(Get Free Report)

Pharvaris N.V. (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways.

The company’s lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121.

See Also